Exagen Diagnostics has entered into an agreement with non-profit health services company CareFirst BlueCross BlueShield to clinically study its AVISE Lupus test.

Under the terms of the agreement, certain CareFirst members will gain access to the test that is designed to assist in the differential diagnosis of systemic lupus erythematosus (SLE).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

SLE is known to be the most common form of lupus, which is an incurable autoimmune rheumatic disease. SLE is considered difficult to detect and currently lacks diagnostic tests.

“The test and algorithm have been prospectively validated in clinical trials conducted in a total of over 1,200 patients. AVISE Lupus is said to have demonstrated better diagnostic accuracy compared to standard biomarkers.”

AVISE Lupus test is a ten-marker diagnostic that comprises cell-bound complement activation products (CB-CAPs) and SLE related markers. It is designed to maximise accuracy and minimise time to diagnosis.

The test and its algorithm have been prospectively validated in clinical trials conducted in a total of more than 1,200 patients. AVISE Lupus is said to have demonstrated better diagnostic accuracy compared to standard biomarkers alone.

The primary objective of the latest study is to evaluate the efficacy and cost-effectiveness of the test in primary care as well as rheumatology settings.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CareFirst plans to use the study findings to ensure maximum benefit to patients while making coverage decisions for AVISE Lupus in the future.

Exagen Diagnostics chief medical officer Arthur Weinstein said: “This is a unique collaboration which has the potential of ultimately benefitting patients with SLE by enabling earlier diagnosis and consequently earlier and more appropriate treatment.”

As part of the agreement, Exagen and CareFirst will also conduct an exploratory study to investigate the impact of AVISE Lupus test results on primary care physician practice referral patterns.